- Home
- IFRX vs TOYO Comparison
IFRX vs TOYO Comparison
Compare IFRX & TOYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- TOYO
- Stock Information
- Founded
- IFRX 2007
- TOYO 2022
- Country
- IFRX Germany
- TOYO Japan
- Employees
- IFRX N/A
- TOYO N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- TOYO
- Sector
- IFRX Health Care
- TOYO
- Exchange
- IFRX Nasdaq
- TOYO NYSE
- Market Cap
- IFRX 65.8M
- TOYO 153.8M
- IPO Year
- IFRX 2017
- TOYO N/A
- Fundamental
- Price
- IFRX $0.81
- TOYO $3.60
- Analyst Decision
- IFRX Strong Buy
- TOYO
- Analyst Count
- IFRX 4
- TOYO 0
- Target Price
- IFRX $7.75
- TOYO N/A
- AVG Volume (30 Days)
- IFRX 334.9K
- TOYO 13.5K
- Earning Date
- IFRX 08-07-2025
- TOYO 08-21-2025
- Dividend Yield
- IFRX N/A
- TOYO N/A
- EPS Growth
- IFRX N/A
- TOYO 350.49
- EPS
- IFRX N/A
- TOYO 1.09
- Revenue
- IFRX $140,242.00
- TOYO $176,957,128.00
- Revenue This Year
- IFRX N/A
- TOYO N/A
- Revenue Next Year
- IFRX $6,309.47
- TOYO N/A
- P/E Ratio
- IFRX N/A
- TOYO $3.31
- Revenue Growth
- IFRX 30.90
- TOYO 183.69
- 52 Week Low
- IFRX $0.71
- TOYO $1.36
- 52 Week High
- IFRX $2.82
- TOYO $7.22
- Technical
- Relative Strength Index (RSI)
- IFRX 38.07
- TOYO N/A
- Support Level
- IFRX $0.78
- TOYO N/A
- Resistance Level
- IFRX $0.83
- TOYO N/A
- Average True Range (ATR)
- IFRX 0.05
- TOYO 0.00
- MACD
- IFRX 0.03
- TOYO 0.00
- Stochastic Oscillator
- IFRX 61.00
- TOYO 0.00
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About TOYO TOYO CO LTD
Toyo Co Ltd along with its subsidiaries, is engaged in research and development, production, and sales of solar cells. Geographically, the company generates revenue from Asia and the USA, out of which the majority of revenue is generated from Asia.